Vaccine Offers Current Defense Against Equine Influenza

Zoetis partners with Gluck Center to confirm relevant disease protection against new strains.
Share
Favorite
Close

No account yet? Register

ADVERTISEMENT

The pharmaceutical company Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that Fluvac Innovator, the first equine influenza virus (EIV) vaccine, can provide a demonstrated cross-reactive immune response against emerging EIV strains.

Their most recent study demonstrated an immune response against the Richmond 07 strain. Although Richmond 07 is not circulating in the United States, it might be a threat to horses with international exposure.

To help ensure vaccines offer current protection, the World Organization for Animal Health (OIE) encourages vaccine manufacturers to work with laboratories, such as the Gluck Center, that can test for reactivity against circulating strains.

With test studies against six EIV strains since 2002, Zoetis continues its legacy of evaluating the Fluvac Innovator line of vaccines to help ensure the most relevant protection

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.

Share

Written by:

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

Where do you primarily feed your horse?
312 votes · 312 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!